Targeted agents directed against EGFR, such as cetuximab and panitumumab, and those directed against VEGF, such as bevacizumab, have been shown to facilitate a more immunogenic tumor profile in preclinical models and, as such, are reasonable potential adjuncts to ICIs in MSS CRC. This evidence concerns the gene VEGFA and neoplasm.